Distinguishing intestinal tuberculosis (ITB) from Crohn's disease (CD) is diffi cult, although studies have reported clinical, endoscopic, imaging, and laboratory fi ndings that help to differentiate these two diseases. We aimed to produce estimates of the predictive power of these fi ndings and construct a comprehensive model to predict the probability of ITB vs. CD.
INTRODUCTION
Diff erentiating intestinal tuberculosis (ITB) from Crohn's disease (CD) remains a challenging clinical problem in regions where ITB is prevalent and CD incidence is increasing. Th is diff erentiation is also increasingly a problem in countries where ITB is not common, but rapidly growing immigrant populations from areas of high ITB prevalence make ITB an important diagnostic possibility. A defi nite diagnosis of ITB depends on methods that have unsatisfactorily low sensitivities, including 5.3-37.5% for acidfast bacilli tissue staining ( 1-3 ), 23-46% for mycobacterial culture ( 4, 5 ) , and 36.4-67.9% for PCR ( 3, 4, (6) (7) (8) . Th erefore, ITB still cannot be confi dently excluded even when all the above results
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Intestinal Tuberculosis from Crohn's Disease are negative, thus the current Asia-Pacifi c guidelines recommend 8-12 weeks of empirical antituberculosis treatment for patients with diagnostic uncertainty, owing to the potentially fatal complications if immunosuppressive agents are wrongly prescribed to ITB patients ( 9 ) . However, antituberculosis treatment can cause many side eff ects and facilitate the development of Mycobacterium tuberculosis drug resistance. Additionally, 8-12 weeks of empiric antituberculosis treatment can delay proper CD treatment and lead to severe fl ares and complications. Th erefore, many studies have been undertaken to identify features that can diff erentiate between these two diseases, and have found that individual clinical, endoscopic, imaging, and serologic laboratory fi ndings help to guide physicians in selecting empirical treatment ( 1, 4, 6, (10) (11) (12) (13) (14) (15) (16) (17) . However, the results of these studies are heterogeneous with inconsistent fi ndings and recommendations. Th us, physicians need a better model to diff erentiate ITB from CD. Here we report the results of 55 meta-analyses of factors predictive of ITB or CD based on published data, and we present a Bayesian model for discriminating ITB from CD using these factors and the local pretest probability in a publicly available web application.
METHODS

Search strategy and study selection
To obtain all studies related to diff erentiating between CD and ITB, we searched with the term "intestinal tuberculosis" AND "Crohn's disease" for studies published in PubMed, Medline, and Embase from the origination of each database up to September 2015. We included studies that used any of the following to diff erentiate CD from ITB: clinical manifestations, infl ammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), colonoscopic fi ndings, pathologic fi ndings, computed tomography (CT) fi ndings, serological tests including antiSaccharomyces cerevisiae antibody and interferon-γ release assay (IGRA), or a PCR-based assay performed on either tissue biopsies or stool. We included all studies without language restriction. In cases where there was a suspicion of overlapping study populations, the larger study population was selected for inclusion. Duplicate articles were manually deleted. We excluded (i) studies that did not report the number of patients (e.g., reported only the number of mucosal biopsies), (ii) studies that included only complicated cases requiring surgery, and (iii) studies published before the year 2000 that used imaging, owing to the potential for relatively poor imaging quality.
Data extraction and quality assessment
Eligible articles were reviewed independently by two investigators (J.L. and A.B.S.). Disagreements were resolved by consensus and, as necessary, involvement of a third reviewer (P.D.R.H.). All variables to distinguish CD from ITB were recorded. We selected the variables that were included in at least three studies in our analyses. In total, we included age, gender, 14 clinical manifestations, 3 infl ammatory markers, 18 colonoscopic fi ndings (10 for lesion characteristics, 8 for location of involvement), 11 pathologic fi ndings, 5 CT fi ndings, and 2 serological fi ndings (anti-Saccharomyces cerevisiae antibody and IGRA). Th ese 55 variables included the 52 dichotomous variables shown in Table 1 , and fi ve continuous variables including age, duration of symptoms, ESR, CRP, and albumin; ESR and CRP were reported in both dichotomous and continuous variables. Th e defi nition criteria of all variables are provided in Supplementary Table S1 online in the Supplementary Documents . A separate random-eff ects meta-analysis was performed for each predictor variable.
We assessed for bias in the studies using the QUADAS-2 tool. Th e tool comprises of four domains: patient selection, index test, reference standard, and fl ow and timing. Th e risk of bias was judged as "low, " "high, " or "unclear. " Th e "unclear" category was used only when insuffi cient data were reported to permit a judgment. A sensitivity analyses including only low-bias studies was performed.
Statistical analyses and development of a Bayesian model to predict the probabilities of ITBs
Meta-analysis of each fi nding was carried out using a randomeff ects model to combine estimates from each study. For the predictor variables with dichotomous results, the diagnostic odds ratio (OR) and corresponding 95% confi dence interval (CI) for CD were calculated to determine the fi ndings that signifi cantly favored CD vs. ITB. Heterogeneity was determined by the I 2 . Positive and negative likelihood ratios (LRs) for both ITB and CD were calculated to determine the eff ect size of each fi nding. For example, to calculate the positive LR for ITB for a particular fi nding, the percentage of ITB patients with the positive fi ndings was divided by the percentage of CD patients with that positive fi ndings. For the continuous variables, the results were reported in mean diff erence and 95% CI.
Th e signifi cant variables with dichotomous results were selected to build the Bayesian model, which calculated the probability of ITB based on the relative prevalence of ITB vs. CD (the pretest probability of ITB) and LR for ITB of each predictor variable in the model. Th e pretest probability is converted into odds, then multiplied by each of the LRs, and then converted back into a probability. Th e formula used is where P 0 is the pretest probability of ITB, which is the relative prevalence of ITB, and P ′ is the post-test probability, which is the probability of diagnosis of ITB. For any fi ndings without available results, the model defaults to an LR of 1 for that fi nding.
For variable selection, because of uncertain cutoff values of heterogeneity and eff ect size to determine which variables should be included to obtain the best model, three models with diff erent cutoff s of the variables' heterogeneity and LR were generated. Th e fi rst model comprises of all variablesthat signifi cantly favored either CD or ITB with low to moderate heterogeneity ( I 2 <50%) and strong eff ect size (LR≥2). Th e second model included all All analyses were performed in R version 3.2.2. Th e package metafor was used for meta-analysis. Th e package OptimalCutpoints was used to create ROC curves and defi ne the cut-point providing the best performance of the model. Th e Bayesian model web application was built in the Shiny web application framework (shiny. rstudio.com).
RESULTS
Studies selected for inclusion
One thousand and fi ft y articles were found in the systematic literature search. Of these, 59 articles (43 full text, 16 abstracts) met the inclusion criteria. Eleven full-text articles were excluded; four of these contained potentially duplicated subjects (18) (19) (20) (21) , two reported only the number of biopsy specimens ( 22, 23 ) , three did not provide the desired data ( 5, 24, 25 ) , one relied on outdated CT techniques ( 26 ) , and one included only complicated surgical cases ( 27 ) . However, we decided to include two other studies with only surgical cases: one where the indication for surgery was for diagnosis in some cases, and the other one was from 1981 when the effi cacy of medical treatment was poor and early surgery may have been indicated ( 28, 29 ) . Th e severity of disease in these two studies appeared comparable to the other studies included. Ten abstracts were excluded because they did not report suffi cient detailed data. Finally, 38 articles (32 full-text articles and 6 abstracts) comprising 2,117 CD and 1,589 ITB patients were included in the analyses ( Figure 1 ). Among these studies, most were published in English. Th ere were two studies published in Chinese and signifi cant variables with low to moderate heterogeneity, regardless of LR. Th e third model included all signifi cant variables regardless of heterogeneity and LR. Th e model with best performance for diff erentiating ITB from CD was selected to be the fi nal model.
To assess the performance of the models, we did a retrospective cohort review of all newly diagnosed CD and ITB patients in Siriraj Hospital, Bangkok, Th ailand from January 2012 to December 2015. Th e criteria for diagnosis of ITB was any of the following: (i) presence of acid-fast bacilli or caseating granuloma in pathological specimens, (ii) tissue culture growing mycobacterial tuberculosis, (iii) presence of proven tuberculosis elsewhere in the body, and (iv) clinical and endoscopic response to antituberculosis treatment without subsequent recurrence. CD was diagnosed based on clinical, endoscopic, and pathological fi ndings with clinical response to CD treatment with at least 6 months follow-up period. Th e clinical manifestations and laboratory data were manually reviewed in medical records (CH.L. and R.B.). Th e endoscopic fi ndings and pathological fi ndings were reviewed by a gastroenterologist (J.L.) and a gastrointestinal pathologist (A.P.), respectively, who were blinded from fi nal diagnosis and any other predictive data. Th e data from this cohort was applied to all models. Th e performance of the model was determined by area under the curve of receiver operating characteristic curves, sensitivity, specifi city, positive predicted value (PPV), and negative predicted value (NPV) to diff erentiate ITB from CD. Th is protocol was approved by an independent ethics committee according to local requirements in Bangkok. Clinical manifestations . Th e duration of disease was longer in CD ( Table 2 ). Seven studies reported the median and seven studies reported the mean duration of symptoms. Th e median duration in CD (6-53.3 months, range 0.3-300 months) was signifi cantly greater than that in ITB (3-23.4 months, range 0-120 months) in fi ve of the studies ( 1, 6, (12) (13) (14) 16, 30 ) . In the other studies, the reported mean duration of symptoms in meta-analysis was 26.5 months (95% CI=15.7-37.3) longer for CD compared with that for ITB ( 2, 11, 15, (31) (32) (33) (34) . Although the studies reporting means had a very high heterogeneity with I 2 of 97.7%, all of the studies showed a longer duration in CD ( Supplementary Figures  online) . However, our Bayesian model based on LRs requires signifi cant dichotomous diff erences. Th erefore, duration of disease could not be included in the model. Diarrhea, hematochezia, presence of perianal disease, and extraintestinal manifestations signifi cantly favored CD, whereas fever, night sweats, lung involvement, and ascites signifi cantly favored ITB. All of them were selected to build the model. Abdominal pain, abdominal mass, presence of intestinal obstruction, weight loss, and anemia were not signifi cantly diff erent between CD and ITB.
Infl ammatory markers . ESR was reported in continuous values in six studies (four for mean and two for median) ( 1, 11, 12, 15, 17, 34 ) and in dichotomous results (normal vs. abnormal value) in four studies ( 2, 33, 35, 36 ) . Meta-analyses were performed separately. Th ere was no diff erence between the proportion of patients with high ESR among the studies reporting dichotomous results. Patients with ITB had higher ESR level than patients with CD among the studies reporting mean, but the mean diff erence was quite small, at 4.09 (2.22-5.96) mm/h ( Supplementary Figures  online) . Th erefore, ESR was not included in the model. CRP was reported in continuous value in seven studies (fi ve for mean and two for median) ( 2, 12, 13, (35) (36) (37) (38) and in dichotomous results in three studies ( 11, 15, 34 ) . Th e proportion of patients with high CRP was signifi cantly higher in CD in the studies reporting dichotomous results; however, CRP level tended to be higher but not statistically signifi cant in ITB among the studies reporting CRP in mean ( Supplementary Figures online) . Owing to these confl icting results, CRP was not included in the model.
Albumin level was reported in six studies ( 1, 11, 12, 15, 34, 35 ) . Th ere was no signifi cant diff erence in the albumin level between CD and ITB, and it was not included in the model.
Endoscopic fi ndings .
Th e following endoscopic fi ndings significantly favored CD: longitudinal ulcers, aphthous ulcers, cobblestone appearance, luminal stricture, mucosal bridge, and skip lesions. Transverse ulcers and a patulous ileocecal (IC) valve signifi cantly favored ITB. All of them were selected to build the model. Pseudopolyps did not distinguish the two diseases. Mucosal nodularity was found more oft en in ITB, but this was not statistically signifi cant.
For the site of involvement, rectal and sigmoid colon involvement were signifi cant predictors of CD, while involvement of the IC valve and cecum signifi cantly favored ITB. Involvement of rectum, sigmoid colon, and cecum were selected to build the model. Involvement of IC valve may be correlated with patulous IC valve. To avoid the possibility of including potentially interdependent variables in the model, patulous IC valve that has been reported as a signifi cant predictor in many studies was selected. Involvement of ileum, ascending colon, transverse colon, and descending colon was not signifi cantly diff erent between CD and ITB.
Pathologic fi ndings . Granulomas were found more frequently in ITB. Some characteristics of the granulomas were signifi cantly associated with ITB such as confl uent granuloma, large granuloma, multiple granulomas per section, submucosal granuloma, and granuloma with surrounding cuffi ng lymphocytes. An ulcer lined by histiocytes also signifi cantly favored ITB, while focally enhanced colitis signifi cantly favored CD. All of these fi ndings had low heterogeneity and were initially selected to build the model. However, the presence of a confl uent granuloma may be correlated with the presence of large or multiple granulomas/section. Only confl uent granuloma, which had the least heterogeneity and highest positive LR was selected for the model. Microgranulomas and disproportionate submucosal infl ammation were observed more commonly in CD and ITB, respectively, but the diff erences were not signifi cant. Th ey were not included in the model.
Imaging fi ndings .
Four studies using CT were included; all used the CT enterography technique. Th e presence of wall stratifi cation, comb sign, and fi brofatty proliferation signifi cantly favored CD, while short segmental involvement signifi cantly supported the diagnosis of ITB. Th ese predictors were selected to build the model. Asymmetrical wall thickening was found more commonly in CD, but the diff erence was not statistically signifi cant. Th e presence of necrotic intra-abdominal lymph nodes was found only in ITB. Because we considered this as a diagnostic fi nding for ITB, we did not include it as a predictive variable.
Serological testing results .
IGRA has a pooled sensitivity of 84% and a specifi city of 86% for diagnosis of ITB. Its positive result strongly favored ITB ( I 2 =35.3%, positive LR for ITB=5.87), and it was selected to build the model. A positive anti-Saccharomyces cerevisiae antibody favored CD, but it was not statistically significant, and was not included in the model. Supplementary Table  S3 online. Sensitivity analyses using only the studies with low bias were carried out and are summarized in Supplementary Table S4 online in the Supplementary Documents . Sensitivity analyses were not performed for some predictor variables because very few studies qualifi ed aft er the exclusion of studies with high or unclear bias. Th e results of the sensitivity analyses largely confi rmed the results of the initial meta-analyses with the following exceptions: the clinical manifestation of intestinal obstruction and the presence of asymmetrical bowel wall thickening on computed tomographic enterograph became signifi cant in favoring CD with low heterogeneity, and these predictors were added to the model development. Th e heterogeneity was reduced for the presence of night sweats and the presence of comb sign on computed tomographic enterograph.
Sensitivity analysis by QUADAS-2 bias level . Th e evaluation of bias with the QUADAS-2 tool is shown in
Development of the Bayesian model for predicting the probability of ITBs
Th e predictor variables with signifi cant OR were selected to build the model. Th ree models using diff erent criteria for the heterogeneity and LR of predictor variables as we described in the Methods section were shown in Table 3 . In the models, we retained the LR from the original analysis for most predictor variables. We used the LR from the low bias sensitivity analysis for the predictor variables that became signifi cant or had reduced heterogeneity in the low bias sensitivity analysis. Th e model uses local relative prevalence of ITB vs. CD for the pretest probability, and calculates the probability of ITB based on the measured predictor variables. Predictor fi ndings that are not assessed are assigned an LR of 1.
To compare the performance of each of the three models, a validation cohort was identifi ed in Bangkok, Th ailand. Th e three models were applied to the data of 27 CD patients and 22 ITB patients. Because the diff erences between each model were found only in the gender, clinical manifestations, and endoscopic fi ndings parameters (only these had predictors with low LRs or high heterogeneity) ( Table 3 ), the calculated probability of ITB based on these parameters was selected for the three model comparison. Th e ROC curves of all three models are shown in Figure 3 . Th e sensitivity, specifi city, PPV, NPV, false positive (misdiagnosis of ITB in CD patients), and false negative (misdiagnosis of CD in ITB patients) for the cut-point to obtain the best model performance and the cut-point to obtain the NPV of 100% for diagnosis of ITB (avoiding a potentially fatal outcome from wrongly prescribing immunosuppressive agents to patients with ITB) of each model are shown in Table 4 . Th e area under the curve of receiver operating characteristic curves of Model 1, Model 2, and Model 3 were 0.870, 0.920, and 0.921, respectively. Both Model 2 and Model 3 appear to be quite accurate. When we evaluated the best cut-point to obtain an NPV of 100% for diagnosis of ITB, the number of false positives were 15, 15, and 17 for Model 1, Model 2, and Model 3, respectively. Model 2 was selected as the fi nal model because it had an area under the curve of receiver operating characteristic curve comparable to Model 3, but had fewer false positives using a cutpoint to obtain an NPV of 100%. When the pathological data was added to this model, the area under the curve of receiver operating characteristic curve of Model 2 increased to 0.943 (0.875-1.011) ( Figure 4 ). At the cut-point of 85.83% of the probability of ITB, the sensitivity, specifi city, PPV, NPV, and accuracy for diff erentiating ITB from CD were 90.9%, 92.6%, 90.9%, 92.6%, and 91.8%, respectively. Moreover, when the cut-point of 49.04% was used to obtain a NPV of 100% for diagnosis of ITB, the number of patients with CD who would be misdiagnosed with ITB decreased to 5/27 (18.5%). Th e data for predictors of CT enterography and IGRA was available in only 16 patients and one patient, respectively, in our cohort. Th erefore, the full model performance could not be assessed in this validation cohort.
Model access
Readers with estimates of the local prevalence of ITB vs. CD can access and use the model in an individual patient with the Shiny web application at https://www.pathology.med.umich.edu/shiny/ tbcrohns/ or bit.ly/ITBvsCD . Users with an estimate of the pretest probability of ITB can choose for each predictor whether the fi nding is present, absent, or not assessed, and estimate the probability of ITB and CD in their patient.
DISCUSSION
Th is meta-analysis and Bayesian model summarizes the reported factors helpful in diff erentiating CD and ITBs. We selected predictor variables with a signifi cant OR and low heterogeneity, and built a Bayesian model incorporating pretest probability and diagnostic LRs to produce estimates of the probability of ITB and CD that are calibrated to local prevalence. Th e model was validated and demonstrated a high accuracy in diff erentiating ITB from CD in our validation cohort from Bangkok, Th ailand.
Regarding the diff erentiation of ITB from CD, diff erent diagnostic scoring systems have been developed, but unfortunately there is little agreement on which factors to include. Recently, Jung et al. ( 39 ) proposed a model with good performance based on the results of a large retrospective cohort in seven centers in Korea, but the model has not been validated outside of Korea. Th ere have been three recent published meta-analyses carried out to determine the utility of pathologic fi ndings and single serological tests such as anti-Saccharomyces cerevisiae antibody and IGRA (40) (41) (42) . Th is meta-analysis integrates data from all published studies from inception to September 2015 on 55 distinct predictors and they can then calculate whether adding CT enterography or IGRA results will change the probability enough to change their treatment decision. Th e main strength of this study is that it is the largest series of meta-analyses evaluating predictor variables that have been reported to help diff erentiate CD from ITB. We collected all published studies without language restriction, most of which have been performed in Asia; therefore, the results should be generalizable to populations in which ITB prevalence is fairly high. Sensitivity analyses were performed in diff erent criteria of variable selection, and the model with best performance was selected. Th e model demonstrated a high accuracy in diff erentiating ITB from CD in our validation cohort. However, the results were based on a small number of patients, and we have not validated the model when the CT enterography fi ndings and IGRA are included. We would hope that additional predictor data would enhance the performance of the model, but that remains to be proven in a larger data set. Future studies with larger and diff erent populations, and with the availability of all parameters are needed.
Th is study has several limitations. We included studies with large heterogeneities. Across studies, there is signifi cant heterogeneity in sample populations by ethnicity, race, and disease severity. Th ere may be local variation in subjectively evaluated fi ndings such as endoscopic lesions, pathologic fi ndings, and imaging characteristics. We tried to reduce this variance by excluding some studies that have a high potential for bias. For instance, we excluded the studies with a high potential for bias in subject selection by excluding studies that recruited only complicated cases requiring surgery. We also excluded studies using older generation imaging techniques as these results may not be comparable to those using current imaging techniques. Furthermore, we performed sensitivity analyses including only the studies with low bias that confi rmed the signifi cance of the parameters we selected to build the model.
Another limitation is that the structure of our Bayesian model is based on LRs, thus we could only incorporate dichotomized variables, such as the presence or absence of a fi nding. Continuous variables were not incorporated. Furthermore, our model is based on the assumption that each variable is independent of the other variables in the model, as many of these variables have been reported as independent predictors for diff erentiating ITB from CD in previous studies ( 6, 11, 33 ) . We also did deliberately exclude three potentially interdependent variables from the model when they were, by defi nition, likely to be highly correlated with other predictors. For example, we selected confl uent granuloma and excluded large granulomas and high numbers of granulomas, and we selected patulous IC valve and excluded the fi nding of IC valve involvement. Next, the model can be applied only for the diff erentiation of CD and ITB in patients where other potential diagnoses have been already excluded. Moreover, we did not include abstracts that did not provide adequate information, thus there may be other data that could aff ect our results. Last, this model relies on the availability of an estimate of the local pretest probability of ITB to calculate the probabilities, thus it needs external validation in various populations. We invite other groups to validate the model in their local population.
summarizes the fi ndings that have proven useful in diff erentiating these two conditions.
Th is study confi rms that common clinical manifestations infrequently help to make a diagnosis between ITB and CD. Abdominal pain, weight loss, or anemia was not signifi cantly diff erent between the two diseases. Some other common manifestations were found to be signifi cantly diff erent, but their diagnostic value was limited because of their small eff ect size, such as fever for ITB. Th e signifi cant manifestations with high positive LR that are strong predictors, such as the presence of perianal disease, extraintestinal manifestations for CD, night sweats, lung involvement, and ascites for TB, are uncommon fi ndings; all were present in less than half of patients. Furthermore, some endoscopic fi ndings that are strong predictors, such as longitudinal ulcers, cobblestone appearance, and rectal involvement for CD, and transverse ulcers and patulous IC valve for ITB, are also uncommon fi ndings; none of these fi ndings were reported in more than half of the patients. Moreover, while the pathologic fi nding of granulomas, whether confl uent, large, or present in high numbers, strongly favors the diagnosis of ITB, granulomas were found in only 38% of CD and 64% of ITB in this meta-analysis. All of these fi ndings indicate that conventional tools are useful, but that integration of multiple parameters is necessary to produce a strong positive or negative diagnostic probability. Our study results showed that integration of signifi cant clinical manifestations, endoscopic, and pathological fi ndings could accurately diagnose ITB and CD in 91.8% of patients in a validation cohort. Th ese results need more validation in larger studies.
Owing to the limited value of clinical, endoscopic, and pathologic fi ndings in distinguishing these two diseases, new tools have been developed for this purpose. Th e IGRA has performed well in diff erentiating CD and ITB in previous studies. Its pooled sensitivity and specifi city were 84% and 86%, respectively, in this meta-analysis. Th ese data are consistent with another recent metaanalysis ( 41 ) . However, this test is not available in all centers, and can be positive in either active or latent tuberculosis ( 43 ) , which can lead to a misdiagnosis of ITB in CD patients who have been exposed to tuberculosis. Imaging with CTE has shown some promising fi ndings. Demonstration of peritoneal thickening or ascites or short segmental involvement support the diagnosis of ITB. Th e comb sign, fi brofatty proliferation, asymmetrical wall thickening, and wall stratifi cation support the diagnosis of CD. However, there is risk of kidney injury from contrast and additional risks of radiation exposure, thus selecting the patients who will obtain the most benefi t based on pretest probability is warranted.
Th is study developed a Bayesian model that comprised of the signifi cant parameters based on meta-analytic results to calculate the estimated probability of either ITB or CD in an individual patient. Th is model considers the eff ect of each variable independent of whether the results are positive or negative. Furthermore, physicians are able to use the model by selecting only the variables available in their center or in each particular case (unmeasured variables have an LR=1). In addition, this model may help to decrease unnecessary additional testing. For example, physicians can calculate the probability of ITB or CD based on clinical, endoscopic, and pathologic predictors. With this estimate in hand, Th is study addresses a common clinical problem by summarizing the fi ndings of 55 meta-analyses to identify estimates for the predictors that diff erentiate between CD and ITB and by providing a Bayesian model to help physicians calculate the estimated probability of CD or ITB to make treatment decisions with greater confi dence in cases of diagnostic uncertainty.
